Oral deucrictibant for on-demand treatment of hereditary angioedema attacks: a phase 3, multicentre, randomised, double-blind, placebo-controlled crossover trial.

Oral deucrictibant significantly speeds symptom relief compared to placebo in hereditary angioedema attacks, with no severe or serious treatment-related adverse events reported.

• Why it matters: Hereditary angioedema is a rare condition with limited on-demand treatment options that are both effective and easy to administer, creating an unmet medical need.
• What they did: A phase 3, double-blind, crossover trial involving adolescents and adults (aged ≥12 to 12) tested deucrictibant, an oral bradykinin B2 receptor antagonist, for on-demand attack treatment, with p<0·0001 indicating statistical significance.
• The result: Deucrictibant provided faster symptom relief than placebo and was generally well tolerated, supporting its potential as the first oral treatment for bradykinin-mediated angioedema attacks.